Advertisement

Topics

Akers Biosciences enjoys stellar second quarter with sales up 25% year-on-year

12:49 EDT 3 Aug 2017 | Proactive Investors

Rapid diagnostics specialist Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) said quarterly sales were the strongest since the company’s admission to America’s NASDAQ market in 2014. Revenues were US$1.2mln for the three-month period ended June 30, up around 25% on the same period last year and 1.8-times the turnover recorded in the first-quarter. Sales were derived from all of its main markets – the US, China and the rest of the world – and spread across its main product lines, including its breakthrough rapid heparin allergy test. The company has developed a range of breath-test diagnostics which monitor conditions such as oxidative stress, cholesterol levels and whether the body is burning fat.

Original Article: Akers Biosciences enjoys stellar second quarter with sales up 25% year-on-year

NEXT ARTICLE

More From BioPortfolio on "Akers Biosciences enjoys stellar second quarter with sales up 25% year-on-year"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Respiratory
Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...